Can losartan (an angiotensin‑II receptor blocker) cause a cough, and should it be discontinued if a patient develops a new persistent cough?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 26, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Losartan and Cough

Losartan rarely causes cough and is specifically recommended as the preferred alternative for patients who develop ACE inhibitor-induced cough. 1, 2

Incidence of Cough with Losartan

  • In patients with a history of ACE inhibitor-induced cough, losartan causes cough in only 17–36% of cases, compared to 62–87% with ACE inhibitors—a rate similar to placebo (26–35%) or hydrochlorothiazide (25%). 1, 3, 4, 5

  • The FDA label for losartan explicitly states that two prospective, randomized, controlled trials demonstrated that "the incidence of cough associated with losartan therapy, in a population that all had cough associated with ACE-inhibitor therapy, is similar to that associated with hydrochlorothiazide or placebo therapy." 3

  • Losartan does not inhibit angiotensin-converting enzyme and therefore does not cause accumulation of bradykinin or substance P—the mediators responsible for ACE inhibitor-induced cough. 2

Clinical Recommendation

  • The American College of Cardiology/American Heart Association provides a Class I, Level A recommendation (highest level) for switching to an ARB like losartan in patients who cannot tolerate ACE inhibitors due to cough. 1, 2

  • If a patient develops persistent dry cough while taking an ACE inhibitor, discontinue the ACE inhibitor immediately and substitute with losartan or another ARB. 1, 2

  • Cough from ACE inhibitors typically resolves within 1–4 weeks after discontinuation (median ~26 days), though some patients may require up to 3 months. 1, 2

Important Caveats

  • While extremely rare, isolated case reports exist of losartan-induced cough. 6 The FDA label acknowledges that "cases of cough, including positive re-challenges, have been reported with the use of losartan in postmarketing experience." 3

  • However, observational studies show that when cough occurs with losartan, 91% of patients had previously been prescribed an ACE inhibitor and 86% had previously experienced ACE inhibitor cough—indicating "carry-over" effects rather than true losartan-induced cough. 7

  • When reports of cough in the first week of losartan therapy are excluded (to eliminate carry-over from prior ACE inhibitor use), the rate of cough with losartan is 3–6 times lower than with ACE inhibitors. 7

Practical Management Algorithm

  1. If a patient on an ACE inhibitor develops persistent dry cough, stop the ACE inhibitor immediately. 1, 2

  2. Switch to losartan 50 mg once daily (or equivalent ARB dose). 8, 4, 5

  3. Monitor for cough resolution over 1–4 weeks; if cough persists beyond 4 weeks, evaluate for alternative causes (GERD, asthma, post-nasal drip, heart failure-related pulmonary congestion). 1, 2

  4. Check baseline renal function and potassium before starting losartan, then recheck within 1–2 weeks. 2

  5. If the rare event of cough developing de novo with losartan occurs (without prior ACE inhibitor exposure), consider alternative diagnoses first before attributing it to losartan. 3, 7

References

Guideline

Management of Dry Cough in Patients Taking ACE Inhibitors

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of ACE Inhibitor-Induced Cough

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Cough and angiotensin II receptor antagonists: cause or confounding?

British journal of clinical pharmacology, 1999

Guideline

Cough Management in Hypertensive Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.